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Learning objectives:  
• To understand the key role of echocardiography in the diagnosis and 
management of hypertrophic cardiomyopathy (HCM).  
• To learn the fundamental features that an echocardiographic report of a 
HCM patient should include.    
• To differentiate sarcomeric HCM from phenocopies based on 
echocardiographic findings.  
• To understand the pros and cons of each echo modality (transthoracic 
(TTE), transoesophageal (TOE), 3-dimensional (3D)) in different clinical 
scenarios.  
• To appreciate the importance of echo monitoring during invasive 



























Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular 
disease, affecting one in 500 individuals in the general population. In 60% of cases, 
HCM presents an autosomal dominant trait due to mutations in genes encoding 
cardiac sarcomeric proteins, and the remaining aetiologies include a variety of 
clinical entities such as glycogen and lysosomal storage disorders, mitochondrial 
diseases or cardiac amyloidosis, among others(1). In all cases, a systematised 
echocardiographic approach is essential to establish the diagnosis of HCM and to 
decide on specific therapeutic strategies. Moreover, echocardiography plays a key 
role in the evaluation and guidance of the different options to tackle obstructive 
HCM (HOCM). Indeed, recent improvements in survival and quality of life in HCM 
might be attributed to several factors, including the development of reliable 
imaging techniques. On top of this, echocardiography provides valuable 
information for the management of HCM regarding other aspects beyond left 
ventricular tract obstruction (LVOTO). This includes sudden cardiac death (SCD) 
prediction, thromboembolic risk stratification and family screening.  
In this article, we review and focus on the current role of echocardiography in the 
diagnosis and management of HCM.  
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Role of echocardiography in the diagnosis and evaluation of HCM 
A systematic echocardiographic approach is essential to establish the diagnosis of 
HCM and should include the following features (summarised in Figure 1). 
 
Left ventricular hypertrophy evaluation  
In individuals with suspected HCM and in relatives of HCM patients, a complete 
evaluation of all left ventricular (LV) segments from base to apex should be 
performed. Measurements of LV wall thickness must be obtained at end-diastole 
and in short-axis views(2). Systematic short-axis views at mitral valve level, at the 
base of papillary muscles and at apex are recommended (Figure 2) to allow 
reliable successive measurements during follow-up.  
The most common LV hypertrophy (LVH) pattern in HCM is the asymmetrical 
thickening of the inter-ventricular septum. However, hypertrophy might be also 
present elsewhere in a non-contiguous manner, extending to the lateral wall, 
inferoseptum or apex(3). This asymmetric distribution of hypertrophy has been 
considered an important diagnostic feature of HCM, as other causes of LVH due to 
increased loading conditions, such as hypertension, tend to exhibit a more 
symmetrical pattern(4). Nonetheless, some elderly patients with hypertension and 
no history of HCM may also present an asymmetric distribution of LVH due to the 
presence of a ventricular septal bulge. Consequently, differential diagnosis may be 
challenging and other features such as a posterior wall >11 mm, the presence of 
abnormal papillary muscles, elongated mitral leaflets, systolic anterior motion 
(SAM) or LVOTO could help in distinguishing HCM and isolated LV septal bulge(5). 
Other patterns of LVH in HCM include non-septal asymmetric hypertrophy, the 
apical form, and the less frequently observed symmetric and concentric pattern(2). 
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When wall thickness is increased in the anterolateral wall or the apex, its 
measurement could be difficult and so imaging acquisition should be particularly 
thorough. Ultrasound contrast agents or three-dimensional (3D) echography could 
be helpful in this context(6,7). 
Moreover, beam alignment and correct orientation are essential to prevent wall 
thickness (WT) overestimation or foreshortening and caution should be exercised 
to exclude right ventricle (RV) structures such as trabeculations and the RV 
moderator band(7).  
 
Accepted two-dimensional echocardiographic HCM diagnostic criteria include:  
- Unexplained maximal WT ≥15 mm (or higher than 2 standard deviations (SD) for 
age, gender, and height) in any myocardial segment.  
- For first-degree relatives of HCM patients, an unexplained maximal WT ≥13 mm 
is also considered diagnostic. 
Asymmetric septal hypertrophy is defined as a septal/posterior WT ratio of >1.3 in 
normotensive patients (>1.5 in hypertensive patients)(7).  
 
In some cases, HCM patients concurrently present RV hypertrophy. Thus, RV WT 
should also be evaluated. A maximal WT ≥5 mm at end-diastolic subcostal or 
parasternal long-axis views at tricuspid chordae level should be considered as a 







Evaluation of systolic function can be challenging in HCM. The classical parameters 
such as ejection fraction (EF) or fractional shortening (FS) are usually normal or 
even increased due to preserved radial contractile function. However, longitudinal 
strain (LS) values using speckle-tracking echocardiography have been reported to 
be decreased in HCM patients despite normal EF(8). Moreover, tissue Doppler 
imaging (TDI) techniques have shown decreased systolic and diastolic velocities 
from very early phases of the disease and also in HCM mutation carriers without 
overt LVH(9).  
Once LVH is present, the lower LS values are found in hypertrophied segments, as 
opposed to normal subjects who show homogeneous strain and strain rates in all 
LV regions(10).  
Later on in the course of the disease, 5-10% of HCM patients develop a “burnt-out” 
phase in which LV dilates, WT regresses and EF decreases(11).,While the 
mechanism is unclear, diffuse myocardial ischaemia due to microvascular 
dysfunction may play a role leading to cell death and fibrosis replacement(12). 
An EF below 50% represents severe systolic dysfunction, and although it is often 
underappreciated, once end-stage HCM develops clinical deterioration is rapid. 
Therefore, the therapeutical approach must be aggressive once EF is <50%(1). 
 
Diastolic function 
Diastolic dysfunction is one of the main causes of dyspnoea in patients with HCM, 
and a transthoracic echocardiogram (TTE) is the preferred technique for its 
assessment. 
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Following the last American Society of Echocardiography (ASE) and the European 
Association of Cardiovascular Imaging (EACVI) guidelines for diastolic function 
assessment(13), four criteria should be included in the evaluation:  
- E/e’ >14. 
- Left atrial volume index >34 mL/m2.  
- Pulmonary vein atrial reversal velocity (Ar-A duration) 30 msec.  
- Peak velocity of tricuspid regurgitation (TR) jet by continuous wave (CW) 
Doppler >2.8 m/sec.  
If two or more of these criteria are met, a diastolic dysfunction grade II or higher is 
present.  
Other parameters such as an E/a ratio >2, an abnormally reduced mitral annular e’ 
velocity (septal <7 cm/sec, lateral <10 cm/sec) or a E-wave deceleration time <150 
ms imply a restrictive LV filling,, and some studies have shown a worse clinical 
outcome in these individuals even when EF is preserved(14).  
 
Assessment of left atrial size  
The left atrium (LA) is often enlarged in HCM patients due to mitral regurgitation 
(MR) and high LV filling pressures.  
Anteroposterior (AP) diameter has been widely used in HCM and has been proven 
useful to predict embolic events, sudden cardiac death and long-term prognosis in 
HCM(15,16,17). However, LA can remodel asymmetrically and LA size measured by 
AP diameter may not always be accurate. Left atrial volume indexed to body 
surface reflects more precisely LA dimension and is the recommended parameter 
to evaluate LA size by the ASE/EACVI because it considers all spatial 
dimensions(18).  
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Assessment of the mitral valve and left ventricular outflow tract obstruction  
 
The MV apparatus should be systematically evaluated in HCM, including leaflets, 
chordae and papillary muscles.  
Most patients with obstructive HCM present elongated anterior and posterior 
mitral leaflets. The average length of the anterior leaflet in these patients is 34 mm 
(compared with 24 mm in normal subjects), leading to an extent into the LV cavity 
above the mitral annulus plane (a mean of 26 mm vs 13 mm in controls)(19). Other 
MV abnormalities typically present in HCM patients are listed in Table 1(7,19).   
Anomalous chordae insertion may tent the mitral leaflet anteriorly towards the 
flow stream, contributing to SAM, which is responsible for LVOTO. Likewise, 
displaced papillary muscles contacting the septum and elongated mitral leaflets 
are implicated in the pathophysiology of LVOTO(19). 
However, SAM is not exclusive of HCM as it can appear in the context of 
hypovolaemia, in hypertensive patients with small ventricles, with inotropes or 
after MV surgery repair(20). Incomplete SAM is considered when the anterior mitral 
leaflet fails to contact the IVS and is considered complete when it contacts the IVS. 
The severity of SAM depends on how long the mitral leaflets contact the IVS during 
systole. Exercise echo can also aid in the assessment of the dynamic component.  
LVOTO, defined as a peak gradient >30 mmHg, is present at rest in one third of 
HCM patients and should be quantified from the apical 5- and 3-chamber view 
using continuous wave (CW) Doppler. LVOTO occurs because of interventricular 
septal (IVS) hypertrophy and narrowing of the LVOT, as well as SAM of the mitral 
valve (MV). Although the threshold of 30 mmHg defines HOCM, it is generally 
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accepted that obstruction becomes haemodynamically relevant when it is ≥50 
mmHg(1).  
LVOTO can be present at rest or after provocative manoeuvres such as standing, 
Valsalva or exercise, which uncovers a third of HOCM patients with no obstruction 
at rest(21) (Figure 3). In the case of patients with a gradient <50 mmHg at rest or 
with bedside manoeuvres but still symptomatic, an exercise echocardiogram is 
mandatory to unmask latent obstruction(21). By contrast, dobutamine 
pharmacological stress echocardiogram is not recommended as it can be poorly 
tolerated due to its β2 vasodilator effect. Regarding nitrates, current ESC 
guidelines still reserve echocardiogram with these drugs to those subjects who 
cannot perform physiologically stressful procedures(1).  
LVOT gradient can be difficult to acquire, especially during stress 
echocardiograms, and it must not be mistaken for the MR jet  (Figure 4).  
Regarding the RV, outflow obstruction can also be present, isolated or combined 
with LVOTO. It is usually caused by the mid-systolic contact of prominent right 
ventricular muscle bundles located in the RVOT. As it can be easily missed, it 




Left ventricular mid-cavity obstruction  
Patients without LVOTO can still present mid-cavity obstruction, which accounts 
for 10% of HCM cases. Subjects with mid-ventricular obstruction are usually very 
symptomatic and do not respond to drugs such as beta-blockers, calcium channel 
blockers or disopyramide. Mid-cavity LV hypertrophy with a normal apical 
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thickness and anomalous papillary muscle insertion are responsible for this 
phenotype, which is commonly associated with apical aneurysms (Video S1 - 
Supplementary Material) and shows a paradoxical apex to base diastolic gradient 
and an aliasing in the sequestered apical area. 
 
Differential diagnosis  
Hypertensive heart disease and athlete’s heart are two situations in which HCM 
differential diagnosis could be considered. Several morphological features that can 
be evaluated with echocardiography can help to distinguish these entities (Table 
2). Furthermore, ECG and family history are always necessary to contextualise the 
echocardiographic findings. For instance, patients with hypertensive heart disease 
or athlete’s heart can fulfil LVH criteria on ECG, but repolarisation abnormalities 
are not as common as in HCM.  
Another important group of diseases to be considered in the differential diagnosis 
of HCM are the so called phenocopies, or non-sarcomeric variants of HCM. These 
include a variety of clinical entities such as glycogen and lysosomal storage 
disorders, mitochondrial diseases, disorders of fatty acid metabolism and cardiac 
amyloidosis (CA)(22,23). In this context, some echocardiographic features are 
important diagnostic red flags (Table 2, Figure 5).  
Regarding CA, recent data suggest that this disease could be extremely frequent(24) 
and it was reported recently that 5% of HCM patients have hereditary 
transthyretin CA(25). Typical features of CA include a granular myocardial texture, 
mild pericardial effusion, thickening of the interatrial septum and atrioventricular 
valves and a restrictive phenotype, as well as reduced EF in advanced stages(22). 
Moreover, a relative apical sparing of longitudinal strain using 2D speckle-tracking 
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echocardiography has been described in CA patients, as opposed to patients with 
other forms of LVH including sarcomeric HCM(26) (Figure 6).  
 
Echocardiography in HCM management  
Echocardiography plays a decisive role in several aspects of HCM management. 
Areas where echocardiography is decisive include: LVOTO management 
(procedure selection and guidance), SCD and embolic risk prediction, risk 
stratification in non-cardiac surgery, and familial screening. 
 
LVOTO management 
Preprocedurural evaluation and procedure selection  
Echocardiography has classically played a crucial role in LVOTO management. It 
was demonstrated in 1971 that SAM is abolished by myectomy(27). Moreover, 
echocardiography has helped to mechanistically understand LVOTO and has 
contributed to the evolution of myectomy from Morrow’s procedure to the current 
extended technique(27).  
When considering a patient for myectomy or alcohol septal ablation (ASA), a 
complete preprocedural echo study should address, firstly, the mechanism of 
obstruction, secondly, the extension of hypertrophy and thirdly, a full assessment 
of MV. Table 3 includes a list of the main features and measurements that should 
be included(1).  
Recently, 3D echocardiography has shown its potential in the preoperative 
scenario. 3D echocardiography can enhance the spatial assessment of the site, the 
septal thickness and systolic mitral leaflet-to-septal contact extent, as well as the 
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aorto-septal angle(21,28,29). Nonetheless, its value in the clinical arena is still 
unknown and it remains predominantly a research tool(29).  
ACCF/AHA guidelines favour myectomy over ASA as first-line therapy in the 
invasive treatment of LVOTO(30,31). By contrast, ESC HCM guidelines consider 
myectomy and ASA as equal procedures although advocate for a pre-interventional 
evaluation to decide(1).  
Echocardiography can contribute to the procedure election process. When the 
LVOTO mechanism is unclear, pre-operative imaging is suboptimal, intrinsic 
severe MR is suspected, or to better assess the MV apparatus, transoesophageal 
echocardiogram (TOE) must be performed(1,31) (Figure 7).  
It has been suggested that a minimum septal thickness 17 mm is necessary to 
consider a patient for LVOTO invasive techniques, but several referral centres 
accept patients with a thinner septal thickness(32).  ASA may be less effective when 
LVH is severe (30 mm) and in those cases it is generally discouraged(1,29). 
Additionally, MV abnormalities cannot be corrected by ASA and if present they 
prompt the election towards myectomy(17,33). In patients with mitral leaflet 
elongation and/or at least moderate MR, different repairing MV procedures can be 
combined at the same time as myectomy(19). When anterior leaflet measures >33 
mm, plication could be considered, particularly if LVH is <20mm. (Figure 8A).  
MR caused by SAM is classically directed posteriorly and laterally and peaks in 
mid-to-late systole. If regurgitation is anteromedially or centrally-directed or the 
peak lasts throughout systole, the mitral apparatus should be examined with 
particular care and intrinsic MV disease should be ruled out(1,17,19) (Figure 8B). 3D-
echo and TOE could be useful when the aetiology and mechanism remains 
unclear(1) (Video S2).  
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Up to 10–20% of patients with HCM have significant MR, independent of SAM, 
including degenerative, rheumatic or congenital aetiologies. It is fundamental to 
differentiate these patients as they would benefit from MV replacement or repair 
(Video S3).  
Echocardiography during myectomy  
Imaging is an integral part of the periprocedural assessment of patients who 
undergo myectomy(34). As direct cardiac visualisation could lead to imprecision in 
the extent of myectomy, intraoperative TOE has become an essential part of the 
procedure and should always be available during the intervention. TOE provides a 
guide to the morphology of the septum and the geometry of the LVOT, 
individualising the resection(19), and has been shown to increase the safety and the 
efficacy of the procedure(19,35).  
Furthermore, intraoperative TOE contributes to surgical planning, evaluates the 
success of resection and MV repair and detects surgical complications (Figures 5 
and 6). Intraoperative TOE can provide an immediate assessment after weaning 
from bypass pump(7) and can recognise suboptimal surgical results by residual 
obstruction or more than mild MR.  
Taking into account the haemodynamic conditions under general anaesthesia 
during the procedure, isoproterenol administration or premature ventricular 
contraction (PVC) evaluating post-extraystolic potentiation (Brockenbrough 
manoeuvre), could be considered to assess an adequate resection(36). Gradients >25 
mmHg or post-PVC >50 mmHg as well as more than mild MR should lead to 
revision and further resection or MV repair if appropriate(36).  
TOE can also detect complications such as ventricular septal defects (VSD) and 
aortic regurgitation (both appear in <1% of cases) at an early phase(1,7,33). 
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Postoperative echocardiographic evaluation should confirm the reduction of LVOT 
gradient, a thinner septum compared with the basal echo, an enlarged LVOT area, 
and absence of SAM and the mitral-septal contact.  
The role of 3D TOE in myectomy is currently mostly unexplored but one study has 
shown a good performance in quantifying the volume and mass of the muscle 
resected(7,29) (Video S2).  
 
Echocardiography and ASA 
Myocardial contrast echocardiography (MCE), which is based on selective 
intracoronary contrast injection, has become an integral component of ASA and it 
is recommended in all patients undergoing ASA. The introduction of MCE has been 
proven to increase the possibility of success and to influence the interventional 
strategy in up to 20% of cases, through changing the selected vessel or cancelling 
the procedure(37). Among other advantages, MCE enables a reduction of ethanol 
and fluoroscopy time, the infarct size and the incidence of complications(34).  
In MCE, echo contrast or agitated X-ray contrast is injected through the inflated 
balloon catheter(37). Echo shows the opacified myocardium, delineating the area of 
perfusion. This area has to be adjacent to and extend beyond the point at which the 
anterior leaflet of the MV contacts the septum and where the maximal flow 
acceleration concurs(37) (Video S4). MCE typically increases echo density in a 
delineated area of the basal septum(7) (Video S5).  
The territory supplied by the perforators can be very variable and can include the 
moderator band, papillary muscles, the distal septum, the lateral wall and even the 
RV wall(33,34). Before alcohol is injected, absence of opacifying remote territories 
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should be checked. If contrast cannot be localised exclusively at the basal septum, 
the procedure should be cancelled.  
In most centres, MCE is performed by TTE. Multiple views including parasternal 
long-axis and short-axis as well as 4- and 3-chamber apical views can be used to 
delimit opacification of target and non-target regions. The main limitations of TTE 
include the difficulty of continuous monitoring and the suboptimal quality images 
in supine position(7,34).  
For these reasons, TOE is an alternative. It provides better images although the 
required sedation/general anaesthesia can alter the loading conditions and 
interfere with LVOT gradient evaluation(7).  
Intraprocedural echo is useful for evaluating the results. The basal septum, 
infarcted by alcohol, shows typically an increased echogenicity, decreased 
thickening and excursion(7,34). When MR is due to SAM, usually a reduction or 
elimination can be also seen(7) (Video S5).  
Regarding LVOTO, many patients demonstrate a triphasic haemodynamic 
response. Firstly, an immediate marked decrease due to myocardial stunning or 
oedema appears (Figure 9); secondly, a recovery up to 50% of the pre-procedure 
gradient and finally, a progressive reduction over weeks to months due to scarring 
and thinning. Definitive results can take up to several months(37). 
Procedure complications that should be monitored include VSD, cardiac 






Echocardiography in patients with mild hypertrophy  
Some patients present mild septal thickness (16 mm at the point of the mitral 
leaflet septal contact) and are therefore not suitable for classic myectomy or ASA 
due to the risk of iatrogenic VSD(1,30).  
In these cases, inserting a dual-chamber pacemaker (PM) is an option and 
biventricular pacing has also shown promising results in preliminary studies(38) 
with a randomised controlled trial under way (NCT01614717).  
Echo is rarely required for PM implantation. Nonetheless, after the procedure, TTE 
could be useful to evaluate the reduction in LVOTO. More recently, TTE has gained 
relevance in this setting to optimise biventricular pacing. Echo can show the best 
AV delay based on LVOT gradient and transmitral flow(7,34) (Figure 10).  
Another alternative in these patients is cardiac surgery but swapping the goal from 
septal thickness to abnormalities of the MV and papillary muscles that favour 
SAM(31).  
Catheter-based procedures have also been proposed for this subgroup of patients. 
A successful experience with MitraClip® has been recently reported, shifting the 
residual anterior leaflet edge away from the LVOT by combining it with the 
posterior leaflet (A2 to P2)(39). In this case, TOE during the procedure is essential 




Several parameters currently used to predict SCD are obtained from echo 
images(40). Maximal WT has long been considered a key aspect of SCD risk 
stratification and is included in all stratification scores(1,15,30,40). Different studies 
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reported an increased risk of SCD in patients with a maximal WT of 30 mm, 
although few data are available with extreme LVH (35 mm)(41) and a paradoxical 
reduction in SCD risk has been reported recently in individuals with LVH 35 
mm(42). 
Other proposed factors associated with SCD derived from echo examination are 
LVOTO, LA dilatation, LV aneurysm, LV systolic dysfunction and low TDI 
velocities(30,40,41).  
Almost half of the predictor variables of the ESC SCD stratification risk model(1,16) 
derive from echo:  
- Maximal WT measured at the parasternal short-axis at any level.  
- LA diameter.  
- LVOTO at rest and Valsalva.  
LA volume is probably a more accurate measurement than LA diameter, but no 
data are available on the association between SCD and LA area and volume.  
Despite the fact that blood pressure response has been displaced from the new 
SCD score(1), exercise echocardiography may still have a role in SCD stratification. 
Two recent studies have highlighted its role in exercise capacity evaluation and 
exercise-induced wall motion abnormalities as predictors for adverse 
outcomes(33,43).   
 
Thromboembolic risk  
Patients with HCM face an increased risk of AF and its consequential 
thromboembolic risk, which affects almost 20% of these subjects(1). The widely 
used CHA2DS2-VASc score appears to have a low predictive accuracy in this 
subgroup of patients and therefore it is not recommended(15).   
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An alternative model of thromboembolic risk quantification for HCM has recently 
been proposed(15), in which, AP LA diameter and MWT were independent 
predictors of thromboembolism(15).  
A positive linear relationship between LA diameter and thromboembolic risk at 5 
years was found up to a diameter of 45–50 mm. Over 50 mm, the risk became 
exponential and the prevalence of thromboembolic events when these patients 
were in sinus rhythm was 4.7%(15). Based on these data, it is common practice in 
our unit to initiate anticoagulation in HCM patients in sinus rhythm when LA 
diameter is >50 mm and bleeding risk is low, while ESC guidelines recommend 
screening HCM patients for AF with Holter-ECG every 6–12 months when LA 
diameter is >45 mm(1). 
 
 
Non-cardiac surgery management   
Although HCM patients undergoing high-risk and intermediate-risk non-cardiac 
surgeries have a low perioperative event rate, they have a higher risk of 
complications than patients without HCM(44). 
Echocardiography constitutes a useful tool to provide accurate preoperative risk 
stratification(36) and should evaluate:  
- LV systolic function.  
- Degree of diastolic dysfunction.  
- LVOT gradient and results of prior interventions.  
- MR and abnormalities of MV and subvalvular apparatus.  
- Pulmonary hypertension.  
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Some of these findings could modify surgical management as the presence of MR 
may lead to consider endocarditis prophylaxis(45) and LVOTO could cause acquired 
von Willebrand disease and highlight the need for a more careful coagulation 
approach.  
In high-risk patients, echo monitoring during surgery is desirable. TOE could be 
useful to determine the haemodynamic status, the presence of significant LVOTO 
or SAM, LV filling pressures and LV systolic dysfunction(36).  
 
 
Familial screening  
Echocardiography is the most widely used and practical technique for HCM 
familial screening. Moreover, advances in genetics have led to the identification of 
a large number of genotype-positive/phenotype-negative individuals. 
Echocardiographic studies in these individuals have revealed several parameters 
that are more commonly found despite the absence of overt LVH, justifying a closer 
follow up to detect LVH development. In this sense, TDI has demonstrated a 
reduction in systolic and diastolic velocities and speckle-tracking studies have 
shown impaired regional longitudinal strain as well as apical rotation in genetic 
carriers(7,34,46,47) Other pre-hypertrophic features include(34,48):  
- Abnormalities in the MV apparatus such as elongated mitral leaflets.  
- Papillary muscle hypertrophy.  
- False tendons running parallel to the septum.  
- Myocardial crypts 
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Echocardiography versus cardiac magnetic resonance (CMR) in the diagnosis 
and management of hypertrophic cardiomyopathy 
 
ESC guidelines recommend CMR in patients with suspected HCM who have 
inadequate echocardiographic windows, in order to confirm HCM diagnosis(1). 
Moreover, it could also be considered in patients who meet HCM criteria, in order 
to evaluate cardiac anatomy and determine the presence and extent of myocardial 
fibrosis(1). Table 4 summarises the pros and cons of CMR and echocardiography in 




Echocardiography plays an essential role in the diagnosis and management of 
HCM. Aside from confirming LVH, it provides very valuable information that will 
determine the patients’ treatment in many ways, from SCD and embolic risk 
stratification to family screening or LVOTO treatment. Regarding this last issue, the 
invasive treatment of HCM goes beyond classical myectomy or ASA, as patients 
with HCM frequently present mitral valve abnormities that could require repair or 
replacement and a select group of subjects present mid or apical left ventricular 
obstruction and could benefit from an extended myectomy beyond the LVOT. 
Finally, echocardiography has even proven to be useful in pre-hypertrophic gene 
mutation carriers who present specific TDI, speckle-tracking and morphologic 




Key messages:  
• Transthoracic echocardiography is an essential and very accessible tool for 
HCM diagnosis, and a systematised approach is required to assess both 
morphological and functional specific features. 
 
• When assessing left ventricular hypertrophy, other common clinical entities 
such as hypertensive heart disease or athlete’s heart should be discarded. 
An asymmetric pattern of hypertrophy or concomitant LVOTO or SAM can 
be helpful in this context. 
 
• Differential diagnosis of sarcomeric HCM and the so-called phenocopies can 
be challenging. Classic echocardiographic findings plus new 
echocardiographic technologies such as 2D speckle-tracking are useful to 
identify phenocopies. 
 
• Echocardiography is very useful when choosing the most appropriate 
invasive approach to treat LVOTO and to assist during procedures. During 
myectomy, intraoperative TOE monitors myocardial resection and MV 
repair. Regarding ASA, myocardial contrast echocardiography is 
recommended to delineate the perfusion area and guide the procedure.  
 
• Mitral regurgitation caused by SAM classically presents a postero-lateral jet 
and peaks in mid-to-late systole. When different features are present, the 
mitral valve apparatus should be systematically examined in order to 
discard intrinsic valve disease.  
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• Echocardiography is helpful to initiate thromboembolic prophylaxis in 
HCM, as the anterior posterior LA diameter measured in parasternal long-
axis view is an independent predictor of stroke and systemic embolism.  
 
• Family screening is essential in HCM patients and echocardiography is an 
easily available and very useful technique in this context. Aside from 
diagnosing new HCM cases, it also detects pre-hypertrophic features in 
gene mutation carriers, such as papillary muscle or MV abnormalities or 
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Figure 1. Echocardiographic assessment of HCM: key points.  
 
Figure 2. Left ventricular hypertrophy evaluation in HCM. Short axis views 
(SAX) at mitral valve level (left), mid ventricular level (centre) and apex 
(right). The red arrow indicates maximal wall thickness (MWT) at the apical level. 
 
Figure 3. Exercise echocardiography. Apical 5-chamber view at rest (A) and 
during exercise (C). Continuous Doppler (CW) at the LVOT with a maximum 
pressure gradient of 11 mmHg at rest (B), increasing up to 104 mmHg with 
exercise (D).  
 
Figure 4.  CW at the LVOT showing a dynamic obstruction due to HCM.  This 
curve is typically “dagger” shaped and presents a late peaking velocity (shaded 
red). Caution must be taken to avoid contamination by the mitral regurgitation or 
aortic stenosis jets (shaded blue).  
 
Figure 5. Parasternal long axis views of 4 patients with different diseases 
that cause LVH. 
A. Sarcomeric HCM with an asymmetric septal LVH.  B. Anderson-Fabry disease: 
thickened mitral valve and a relative thinning of the inferolateral wall. C. Danon’s 
disease with a severe concentric LVH. D. Wild-type TTR amyloidosis: Concentric 
LVH, large left atrium and a granular/sparkly myocardium pattern with mild 




Figure 6. Example of longitudinal strain “bull’s eye” plot . A relative apical 
sparing is present with lower LS values in basal and mid-ventricular segments. 
 
Figure 7. Intraoperative transoesophageal echocardiogram (TOE) in a 
patient with HOCM undergoing myectomy.  
A. Longitudinal view (Aortic valve level, 130°). Measurement of maximal wall 
thickness. B. Longitudinal view. Distance from the distal narrowing point to the 
right coronary cusp (RCC). C. Longitudinal view with colour Doppler. Distance 
from the point of anterior mitral valve leaflet contact with the septum to RCC. D. 
Transgastric view. Peak LVOT gradient.  
  
Figure 8. Mitral valve and mitral regurgitation (MR) intraoperative 
evaluation.  
A. Longitudinal view from an intraoperative TOE showing anterior mitral leaflet 
measurement and calcified annulus. B. Colour Doppler showing moderate-to-
severe central MR in the context of intrinsic valve disease.  
 
Figure 9. Basal LVOT gradient and haemodynamic response to ASA.  
A. Basal transthoraric Doppler showing LVOTO.  
B. Myocardial contrast echocardiography delineating the target area in the 
basal septum, with absence of opacifying in remote territories.  
C. Myocardial contrast echocardiography showing increased echogenicity in 
the basal septum, once the alcohol is infused.  
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D. LVOT gradient after alcohol injection in a branch from the first septal 
perforator vessel.  
 
Figure 10. Transthoraric echocardiography optimisation in a HOCM patient 
with resynchronisation therapy.  
A. AV interval optimisation. Final AV of 80 ms with 47% filling of RR interval and 
without A wave truncation. B. VV interval optimisation. From left to right: 1.) LVOT 
gradient in basal echo before CRT-P implantation. 2.) Resting LVOT gradient with + 
30 VV interval. 3.) Vasalva LVOT gradient with + 30 VV interval. 4.) Final VV with 





Table 1. Mitral valve abnormalities in HCM  
 
Mitral valve abnormalities in HCM 
Leaflet abnormalities - Excessive tissue and elongated leaflets.  
- Prolapse. 
- Leaflet mismatch. 
- Calcification.  
Chordae abnormalities - Anomalous insertion. 
- Fibrotic retraction.  
Papillary muscles abnormalities - Hypertrophied.  
- Anterior and basilar displacement of the 
anterolateral papillary muscle. 
- Insertion of anterolateral papillary muscle 
directly into the mid-anterior mitral valve leaflet.  
Annulus - Calcification.  
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Athlete’s heart Cardiac amyloidosis Anderson-Fabry disease 
Left 
ventricle 
- Asymmetric LVH in 
most cases 
- Moderate LVH 
- Concentric 
- Mild to moderate LVH 
- Concentric  
- Enlarged LV 
- Moderate LVH 
- Concentric  






- Increased free wall 
thickness in some 
cases 
- No specific 
abnormalities 
- Physiological dilation - Increased free wall 
thickness 




- Enlarged left atrium - Enlarged left atrium 
in some cases 
- Normal or mildly 
enlarged 
- Enlarged left atrium. 
- Increased interatrial 
septum thickness. 
- Enlarged left atrium 




- No specific 
abnormalities 
- No specific 
abnormalities 




- Thickened atrioventricular 




- Papillary muscles 
abnormalities  
- 30% of patients 
with SAM and LVOTO 
at rest 
- Regression of LVH 
after antihypertensive 
treatment 
- LV thickness decreases 
with deconditioning 
- Pericardial effusion 
- Apical sparing with 
speckle-tracking analysis 
- Binary sign (not specific) 
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Table 3. Echocardiographic preoperative assessment.  
 
Echocardiographic preoperative assessment 
1. Mechanism of obstruction. - Systolic anterior motion (SAM).  
- Mid cavity due to mid-septal hypertrophy.  
- Sub-aortic membrane.  
- Aortic stenosis.  
- Abnormal papillary muscle insertion into the 
anterior mitral leaflet.  
- Accessory papillary muscles producing mid-cavity 
obstruction.  
- Enlarged mitral valve leaflets.  
- Accessory mitral valve tissue.  
2. Extension, width and depth 
of the hypertrophy. 
- Distance from the point of anterior mitral leaflet-
septal contact upwards to the base of the right 
coronary cusp and downwards to the apex (Figure 
7C).  
- Location of the endocardial fibrous plaque.  
- Apical extent of the septal buldge.  
3. Morphological and 
functional assessment of 
mitral valve, annulus and 
papillary muscles.  
- Quantity, direction and timing of mitral 















Table 4: Ecocardiography versus CMR in HCM 
 
 Echocardiography Cardiac magnetic resonance 
Advantages • Availability 
 
• Uncomplicated evaluation of 
dynamic features such as 
left ventricular outflow tract 
obstruction and systolic 
anterior motion. 
 
• Evaluation of diastolic 
function.  
 
•  Myocardial longitudinal 
velocities and deformation 
parameters useful in pre-
hypertrophic states. 
 
• Intraoperative studies 
available to guide myectomy 
or alcohol septal ablation. 
 
• Easily accessible for family 
screening. 
 
• More precise imaging of apical 
segments in apical 
hypertrophic cardiomyopathy. 
 
• Usefulness of tissue 
characterization and late 
gadolinium enhancement 
patterns in differential 
diagnosis. 
 
• Better detection of aneurysms 
and thrombi. 
 
• Assessment of presence and 
extent of myocardial fibrosis. 
 
• Higher sensitivity detecting 
pre-hypertrophic features 




Disadvantages • Limited issue 
characterization. 
 
• Worse imaging of anterior 
and apical segments.  
 
• No direct visualization of 
myocardial fibrosis.  
 




• Evaluation of left ventricular 
outflow tract obstruction and 
systolic anterior motion is less 
accessible and more 
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Video S1. Mid-ventricular obstruction.  
Transthoracic apical 4-chamber view from a patient with HCM and mainly apical and mid-
ventricular hypertrophy with mid-ventricular collapse during systole.  
 
Video S2. 3D intraoperative TOE.  
3D TOE showing moderate-to-severe eccentric and posterior MR in a patient undergoing 
myectomy.  
 
Video S3. Colour Doppler intraoperative TOE showing moderate-to-severe 
mitral regurgitation in a patient undergoing myectomy.  
Calcified mitral annulus and two jets, one central and one eccentric, suggesting a mixed 
aetiology, not optimal for mitral repair. 
 
Video S4. Myocardial contrast transthoracic echocardiogram during ASA.  
Apical 4-chamber view showing opacified area of VM-septum contact after contrast 
injection in the first septal vessel.  
 
Video S5. Intraprocedural transhoratic echocardiogram evaluating ASA 
result.  
Apical colour Doppler 5-chamber view after alcohol injection showing increased 
echogenicity in the septum, absence of SAM or LVOTO and residual mild MR.  
 
